Administrative Core

行政核心

• 批准号: 10707118
• 负责人: Boyi Gan
• 金额: $ 31.35万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-20 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10707118
• 关键词: Achievement; Advisory Committees; Basic Science; Benchmarking; Cancer Patient; Clinical; Cloning; Collaborations; Combined Modality Therapy; Communication; Data; Development; Direct Costs; Doctor of Philosophy; Ensure; Esophageal Adenocarcinoma; Evaluation; Faculty; Funding; Genomics; Goals; Guidelines; Human; Hypoxia; Image; Imaging Device; Immunotherapy; Infrastructure; Institution; Intellectual Property; Iron; Knowledge; Leadership; Malignant neoplasm of esophagus; Malignant neoplasm of lung; Measures; Mus; Myeloid Cells; National Cancer Institute; Office of Administrative Management; Patients; Performance; Policies; Pre-Clinical Model; Principal Investigator; Process; Production; Progress Reports; Radiation; Radiation therapy; Radiation-Sensitizing Agents; Reporter Genes; Research; Research Project Grants; Resistance; Resource Sharing; Resources; Risk; Role; Sampling; Students; Technology; Testing; Therapeutic Agents; Training; Transfection; Transgenic Organisms; Translating; Translational Research; Wages; Work; Xenograft Model; anticancer research; cancer cell; cancer type; chemoradiation; cohort; conflict resolution; data management; data sharing; esophageal cancer patient; interest; meetings; member; molecular imaging; neoplastic cell; novel therapeutics; outreach; peer; programs; radiation resistance; stable cell line; standard of care; therapy resistant; tool; tumor; tumor growth; tumor hypoxia; web site

ADMINISTRATIVE CORE – SUMMARY The proposed Acquired Resistance to Therapy and Iron (ARTI) Center is focused on the role of ferroptosis in acquired resistance to radiation therapy. Radiation therapy is used to treat approximately 50% of cancer patients and is standard of care treatment for lung cancer and esophageal cancer patients. The ARTI Center will focus on these cancer types and comprise three research projects. Project 1 will focus on identifying the mechanisms of ferroptosis in acquired resistance to radiation therapy and testing ferroptosis inducers (FINs) as radiosensitizers. Project 2 will focus on determining whether hypoxia-induced resistance to ferroptosis contributes to acquired tumor resistance to radiation therapy and whether FINs re-sensitize hypoxic tumor cells to radiation treatment. Project 3 will focus on understanding the role of genomic and microenvironment factors in acquired resistance to ferroptosis to chemoradiation in esophageal adenocarcinoma. The three research projects will be supported by one shared Molecular Imaging Core (MIC), which will provide imaging tools and analyses for measuring tumor growth, assessing the ability to overcome acquired radiation resistance using combination therapies (e.g., FINs with radiation therapy or immunotherapy), identifying intratumoral hypoxic regions, and evaluating myeloid cell expansion in conferring ferroptosis resistance to chemoradiation therapy. To support the MIC and these three projects, the Administrative Core (AC) will be established as part of the ARTI Center infrastructure that will support, coordinate, and facilitate all activities aimed at achieving and evaluating milestones across the projects and core. The AC will establish and maintain engagement and communication among ARTI Center and ARTNet members and program officials in Aim 1. In Aim 2, the AC will facilitate ARTI Center evaluation, support the timely and quality development and submission of progress reports, and maintain proper and transparent stewardship of funds. The AC will develop and implement an internal solicitation and prioritization process for Pilot and Trans-Network Projects in Aim 3. In Aim 4, the AC will serve as the central infrastructure to build a website and manage data, materials, resources, conflict resolution, and issues of intellectual property for technologies and tools. The multiple Principal Investigators (mPIs) of the ARTI Center, Boyi Gan, PhD and Albert Koong, MD, PhD, will serve as AC Co-Leaders. Under their leadership, the AC will be able to leverage institutional and divisional resources; to establish and maintain an ARTI Center Advisory Committee; to encourage the development of junior faculty, trainees, and students in cancer research; to promote collaborations across ARTNet; and to ensure abidance by the ARTNet governance and resource and data sharing policies. Overall, the AC will be the central juncture for the ARTI Center to integrate with other ARTNet centers as well as other National Cancer Institute-funded programs and initiatives.

行政核心——总结 拟议的获得性治疗和铁抗性 (ARTI) 中心重点关注铁死亡的作用 对放射治疗的获得性抵抗。放射疗法用于治疗大约 50% 的癌症 患者，是肺癌和食道癌患者的标准护理治疗。 ARTI 中心将 重点关注这些癌症类型，包括三个研究项目。项目 1 将重点确定 铁死亡在放射治疗获得性抵抗中的机制和测试铁死亡诱导物（FIN） 放射增敏剂。项目2将重点确定缺氧是否诱导对铁死亡的抵抗 有助于获得性肿瘤对放射治疗的耐药性以及 FIN 是否使缺氧肿瘤细胞重新变得敏感 到放射治疗。项目 3 将重点了解基因组和微环境因素的作用 食管腺癌对放化疗的铁死亡的获得性抵抗。三项研究 项目将得到一个共享的分子成像核心（MIC）的支持，该核心将提供成像工具和 分析测量肿瘤生长，评估克服获得性辐射抗性的能力 联合治疗（例如 FIN 联合放射治疗或免疫治疗），识别瘤内缺氧 区域，并评估骨髓细胞扩张赋予铁死亡对放化疗的抗性。 为了支持 MIC 和这三个项目，将建立行政核心 (AC)，作为 ARTI 中心基础设施将支持、协调和促进旨在实现和促进所有活动 评估项目和核心的里程碑。审计委员会将建立并维持参与， 在目标 1 中，ARTI 中心和 ARTNet 成员以及项目官员之间进行沟通。在目标 2 中，AC 将 促进 ARTI 中心评估，支持及时、高质量的开发和提交进度 报告，并保持适当和透明的资金管理。审计委员会将制定并实施 目标 3 中试点和跨网络项目的内部征求和优先排序流程。在目标 4 中，审计委员会 将作为建立网站并管理数据、材料、资源、冲突的中央基础设施 解决方案以及技术和工具的知识产权问题。多名首席研究员 ARTI 中心的 mPIs、Boyi Gan 博士和 Albert Koong 医学博士、哲学博士将担任 AC 联合领导人。在下面 在他们的领导下，审计委员会将能够利用机构和部门资源；建立和维持 ARTI 中心咨询委员会；鼓励初级教师、实习生和学生的发展 癌症研究；促进 ARTNet 上的合作；并确保遵守 ARTNet 治理 以及资源和数据共享政策。总体而言，AC 将成为 ARTI 中心的核心枢纽 与其他 ARTNet 中心以及其他国家癌症研究所资助的项目和举措相结合。